EA201291348A1 - Активаторы растворимой гуанилатциклазы - Google Patents

Активаторы растворимой гуанилатциклазы

Info

Publication number
EA201291348A1
EA201291348A1 EA201291348A EA201291348A EA201291348A1 EA 201291348 A1 EA201291348 A1 EA 201291348A1 EA 201291348 A EA201291348 A EA 201291348A EA 201291348 A EA201291348 A EA 201291348A EA 201291348 A1 EA201291348 A1 EA 201291348A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
pharmaceutically acceptable
guanylatzyclases
activators
soluble
Prior art date
Application number
EA201291348A
Other languages
English (en)
Other versions
EA023254B1 (ru
Inventor
Субхарекха Рагхаван
Джон Е. Стелмак
Камерон Дж. Смит
Хун Ли
Алан Уайтхед
Шерман Т. Уодделл
И-Хэн Чэнь
Шоуву Мяо
Ольга А. Орноски
Джои Гарфанкл
Сибинь Ляо
Цзиан Чан
Сяоцин Хань
Цзянь Го
Джонатан А. Грепер
Линда Л. Броканьер
Кит Росоэр
Эмма Р. Парми
Original Assignee
Мерк Шарп Энд Домэ Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Энд Домэ Корп. filed Critical Мерк Шарп Энд Домэ Корп.
Publication of EA201291348A1 publication Critical patent/EA201291348A1/ru
Publication of EA023254B1 publication Critical patent/EA023254B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Соединение формулы Iили его фармацевтически приемлемая соль, способные к модуляции продукции циклического гуанозинмонофосфата ("cGMP") в организме и, как правило, подходящие для профилактики и лечения заболеваний, связанных с нарушением баланса cGMP. Кроме того, изобретение относится к способам получения соединений формулы I или их фармацевтически приемлемых солей, к их применению в лечении и профилактике указанных выше заболеваний и для получения предназначенных для этого фармацевтических средств и к фармацевтическим препаратам, которые включают соединения формулы I или их фармацевтически приемлемые соли.
EA201291348A 2010-05-27 2011-05-24 Активаторы растворимой гуанилатциклазы EA023254B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34906510P 2010-05-27 2010-05-27
PCT/US2011/037718 WO2011149921A1 (en) 2010-05-27 2011-05-24 Soluble guanylate cyclase activators

Publications (2)

Publication Number Publication Date
EA201291348A1 true EA201291348A1 (ru) 2013-06-28
EA023254B1 EA023254B1 (ru) 2016-05-31

Family

ID=45004331

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291348A EA023254B1 (ru) 2010-05-27 2011-05-24 Активаторы растворимой гуанилатциклазы

Country Status (28)

Country Link
US (1) US9365574B2 (ru)
EP (1) EP2575473B1 (ru)
JP (2) JP5409961B2 (ru)
KR (2) KR101499308B1 (ru)
CN (1) CN103096718B (ru)
AR (1) AR081830A1 (ru)
AU (1) AU2011258436B2 (ru)
BR (1) BR112012030177B1 (ru)
CA (1) CA2800541C (ru)
CL (1) CL2012003317A1 (ru)
CO (1) CO6640255A2 (ru)
CR (1) CR20120599A (ru)
DO (1) DOP2012000300A (ru)
EA (1) EA023254B1 (ru)
ES (1) ES2564503T3 (ru)
GT (1) GT201200320A (ru)
HN (1) HN2012002555A (ru)
IL (1) IL223259A0 (ru)
MA (1) MA34330B1 (ru)
MX (1) MX2012013774A (ru)
NI (1) NI201200172A (ru)
NZ (1) NZ603884A (ru)
PE (1) PE20130222A1 (ru)
SG (1) SG185777A1 (ru)
TN (1) TN2012000544A1 (ru)
TW (1) TW201202245A (ru)
UA (1) UA107112C2 (ru)
WO (1) WO2011149921A1 (ru)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3002298T (pt) 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
KR20130132392A (ko) * 2010-07-09 2013-12-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 가용성 구아닐레이트 시클라제의 자극제로서의 고리-융합된 4-아미노피리미딘 및 그의 용도
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102012200356A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Imidazopyridine und Imidazopyridazine und ihre Verwendung
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
DE102012200357A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte Pyrazolopyridine und ihre Verwendung
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
DE102012200354A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung
ES2648810T3 (es) * 2011-07-06 2018-01-08 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de la guanilato ciclasa soluble
AU2012300844B2 (en) * 2011-09-02 2017-03-30 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
DE102012200351A1 (de) 2012-01-11 2013-07-11 Bayer Pharma Aktiengesellschaft Substituierte annellierte Pyrimidine und ihre Verwendung
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
ES2644781T3 (es) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
LT2847228T (lt) 2012-05-10 2018-11-12 Bayer Pharma Aktiengesellschaft Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
BR112015012571B1 (pt) * 2012-11-30 2022-05-24 Astellas Pharma Inc Compostos de imidazopiridina e usos terapêuticos dos mesmos
MX2015010725A (es) * 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
WO2014131760A1 (de) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung
EP2961754B1 (de) 2013-03-01 2016-11-16 Bayer Pharma Aktiengesellschaft Benzyl-substituierte pyrazolopyridine und ihre verwendung
CN109369635B (zh) 2013-03-15 2023-06-30 赛克里翁治疗有限公司 化合物或其药学上可接受的盐及其应用和药物组合物
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
AP2016008970A0 (en) 2013-07-10 2016-01-31 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2015124544A1 (de) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CA2959199A1 (en) * 2014-08-29 2016-03-03 Bayer Pharma Aktiengesellschaft Amino-substituted annulated pyrimidines and use thereof
EP3186251A1 (de) 2014-08-29 2017-07-05 Bayer Pharma Aktiengesellschaft Substituierte annellierte pyrimidine und ihre verwendung
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
TW201625635A (zh) * 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016087343A1 (de) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
US20180169095A1 (en) 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10213429B2 (en) 2015-05-28 2019-02-26 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
DK3325013T4 (da) 2015-07-23 2023-10-16 Bayer Pharma AG Stimulatorer og/eller aktivatorer af den opløselige guanylatcyklase (sgc) i kombination med en inhibitor af den neutrale endopeptidase (nep inhibitor) og en angiotensin aii-antagonist og deres anvendelse
CN108463224A (zh) 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
CA3029374A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators
US10889577B2 (en) 2016-07-07 2021-01-12 Cyclerion Therapeutics, Inc. Solid forms of an sGC stimulator
BR112019004468A2 (pt) 2016-09-02 2019-05-28 Ironwood Pharmaceuticals Inc estimulantes de sgc
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
EP3525779B1 (de) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
EP3538096B1 (en) 2016-11-08 2024-02-28 Tisento Therapeutics Inc. Treatment of cns diseases with sgc stimulators
CN110267949A (zh) 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
EP3609883B1 (en) * 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
US11897887B2 (en) 2017-12-19 2024-02-13 Tisento Therapeutics Inc. sGC stimulators
MX2023004857A (es) 2018-03-07 2023-11-24 Cyclerion Therapeutics Inc Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
KR20210033444A (ko) 2018-06-04 2021-03-26 엑스사이언티아 엘티디 아데노신 수용체 길항제로서 피라졸로피리미딘 화합물
EP3820476A1 (en) 2018-07-11 2021-05-19 Cyclerion Therapeutics, Inc. Use of sgc stimulators for the treatment of mitochonrial disorders
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles
US20210110275A1 (en) * 2019-10-11 2021-04-15 Royal Bank Of Canada System and method of machine learning using embedding networks
US20230130739A1 (en) 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
WO2021202546A1 (en) 2020-03-31 2021-10-07 Cyclerion Therapeutics, Inc. Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
CN111467350B (zh) * 2020-04-20 2021-03-19 黑龙江中医药大学 一种治疗乳腺炎的药物及其制备方法
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
US20240207265A1 (en) 2021-04-20 2024-06-27 Tisento Therapeutics Inc. TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
EP4326722A1 (en) 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Sgc stimulators
WO2022265984A1 (en) 2021-06-14 2022-12-22 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
WO2023018795A1 (en) 2021-08-11 2023-02-16 Curtails Llc Nep inhibitors for the treatment of laminitis
WO2024086179A1 (en) 2022-10-18 2024-04-25 Tisento Therapeutics, Inc. Pyrimidine sgc stimulators
WO2024086182A1 (en) 2022-10-18 2024-04-25 Tisento Therapeutics Inc. Treatment of mitochondrial diseases with sgc stimulators

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB876526A (en) 1957-12-24 1961-09-06 Geigy Ag J R Process for the production of new aminobenzoic acid derivatives and their use in pest control
DE4410997A1 (de) * 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
CA2150609C (en) 1994-06-01 1998-12-08 Mikiro Yanaka Pyrimidine derivatives and pharmaceutical composition
CN1082949C (zh) * 1995-06-06 2002-04-17 辉瑞大药厂 2,4－二氯吡啶类化合物转化为2－芳氧基－4－氯吡啶类化合物的方法
EE9900151A (et) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterotsüklüülmetüül-asendatud pürasooliderivaadid
DE19744027A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19904710A1 (de) 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
DE10054278A1 (de) 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
ES2231581T3 (es) * 2000-11-22 2005-05-16 Bayer Healthcare Ag Nuevos derivados de pirazolopiridina sustituidos con lactama.
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
BR0207975A (pt) 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
WO2003035005A2 (en) 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
PL371678A1 (en) 2002-02-13 2005-06-27 F.Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
US7241803B2 (en) 2002-11-21 2007-07-10 New York Blood Center Compounds for inhibition of HIV infection by blocking HIV entry
US20040121994A1 (en) 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
US20050038183A1 (en) 2003-08-14 2005-02-17 Dongchan Ahn Silicones having improved surface properties and curable silicone compositions for preparing the silicones
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
EP1616965A1 (en) * 2004-07-16 2006-01-18 AXXAM S.r.l. Methods and assays for detecting guanylate cyclase activity
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
AU2006257638A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles
EA200702497A1 (ru) 2005-06-15 2008-06-30 Пфайзер Лимитед Замещенные арилпиразолы для применения против паразитов
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
DE102005031575A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung
RU2008105481A (ru) 2005-07-18 2009-08-27 Байер ХельсКер АГ (DE) Новое применение активаторов и стимуляторов растворимой гуанилатциклазыдля профилактики или лечения почечных расстройств
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US8222262B2 (en) 2006-10-03 2012-07-17 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CA2675511A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
DE102006054757A1 (de) 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
AU2009322836B2 (en) * 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
US8865734B2 (en) 2010-03-18 2014-10-21 Institut Pasteur Korea Anti-infective compounds
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) * 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
KR20130132392A (ko) * 2010-07-09 2013-12-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 가용성 구아닐레이트 시클라제의 자극제로서의 고리-융합된 4-아미노피리미딘 및 그의 용도
DE102010040233A1 (de) * 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung

Also Published As

Publication number Publication date
WO2011149921A1 (en) 2011-12-01
HN2012002555A (es) 2015-09-07
DOP2012000300A (es) 2013-04-30
TW201202245A (en) 2012-01-16
KR20140019004A (ko) 2014-02-13
SG185777A1 (en) 2012-12-28
AU2011258436A1 (en) 2013-01-10
UA107112C2 (en) 2014-11-25
EA023254B1 (ru) 2016-05-31
NI201200172A (es) 2013-04-15
BR112012030177A2 (pt) 2015-11-24
MA34330B1 (fr) 2013-06-01
AU2011258436B2 (en) 2014-06-12
KR20130032329A (ko) 2013-04-01
CN103096718B (zh) 2016-01-20
MX2012013774A (es) 2012-12-17
ES2564503T3 (es) 2016-03-23
JP2013527196A (ja) 2013-06-27
AR081830A1 (es) 2012-10-24
BR112012030177B1 (pt) 2019-08-27
KR101499308B1 (ko) 2015-03-05
CO6640255A2 (es) 2013-03-22
EP2575473B1 (en) 2016-01-20
JP5409961B2 (ja) 2014-02-05
NZ603884A (en) 2014-06-27
JP2014055151A (ja) 2014-03-27
CN103096718A (zh) 2013-05-08
EP2575473A1 (en) 2013-04-10
US9365574B2 (en) 2016-06-14
GT201200320A (es) 2015-02-19
CA2800541A1 (en) 2011-12-01
PE20130222A1 (es) 2013-03-14
CL2012003317A1 (es) 2013-03-08
US20130072492A1 (en) 2013-03-21
CR20120599A (es) 2013-03-13
CA2800541C (en) 2016-03-22
TN2012000544A1 (en) 2014-04-01
IL223259A0 (en) 2013-02-03
EP2575473A4 (en) 2013-11-27
JP5789288B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
MX2017006649A (es) Derivados de triazolo-pirazinilo utiles como activadores de guanilato ciclasa soluble.
TN2018000219A1 (en) Soluble guanylate cyclase stimulators
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
TN2015000368A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX2014003194A (es) 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CA2920410C (en) Thienopiperidine derivative and use thereof
TR201902057T4 (tr) Tetrasiklin bileşikleri.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EA201490573A1 (ru) Соединение бензотиазолона
MY169215A (en) 3-o-heteroaryl-ingenol
WO2013106756A3 (en) Antimicrobial agents
EA201490233A8 (ru) Стабильные лекарственные формы артеролана и пиперахина
EP2593460A4 (en) ANTI-VIRAL BENZYLAMIDE ANIMIRVENTS OF 4-OXO-4H-PYRIDO [L, 2-A] PYRIMIDINE-2-CARBOXYLIC ACID TO RADICALS NITROGEN IN POSITIONS 7 AND 9
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
ECSP12012358A (es) Activadores de guanilato ciclasa soluble

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU